Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 18/20 | 1.00 |
| ▸ | CDK2 | P24941 | 17/20 | 1.00 |
| ▸ | CCNA1 | P78396 | 17/20 | 1.00 |
| ▸ | STING1 | Q86WV6 | 1/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.65 |
| ▸ | CDK1 | P06493 | 1/20 | 0.65 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.65 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.65 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.65 |
| ▸ | CDK9 | P50750 | 1/20 | 0.65 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.61 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.58 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30490739 | 1.00 | FLT3 (1.00) | FLT3CDK2CCNA1STING1CCNT1 | |
| SCHEMBL31123096 | 0.99 | FLT3 (0.98) | FLT3CDK2CCNA1STING1CCNT1 | |
| SCHEMBL31123088 | 0.97 | FLT3 (0.95) | FLT3CDK2CCNA1STING1CCNT1 | |
| SCHEMBL22477939 | 0.86 | FLT3 (0.76) | FLT3CDK2CCNA1STING1CCNT1 | |
| SCHEMBL31123110 | 0.86 | CDK2 (0.75) | FLT3CDK2CCNA1STING1CCNT1 | |
| SCHEMBL22467149 | 0.85 | FLT3 (0.74) | FLT3CDK2CCNA1STING1CCNT1 | |
| SCHEMBL31123084 | 0.85 | CDK2 (0.73) | FLT3CDK2CCNA1STING1CCNT1 | |
| SCHEMBL22466864 | 0.84 | FLT3 (0.72) | FLT3CDK2CCNA1STING1CCNT1 | |
| SCHEMBL22478078 | 0.84 | FLT3 (0.72) | FLT3CDK2CCNA1STING1CCNT1 | |
| SCHEMBL22478080 | 0.84 | FLT3 (0.72) | FLT3CDK2CCNA1STING1CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4688157-A1 | 3H-PYRAZOLO[4.3:f] QUINOLINE-BASED COMPOUNDS AS STING ANTAGONISTS | Purdue Research Foundation (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12384782-B2 | Inhibitors of kinase networks and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2025-08-12 | — | — | US | disclosed |
| WO-2024206164-A1 | 3H-PYRAZOLO[4.3:f] QUINOLINE-BASED COMPOUNDS AS STING ANTAGONISTS | PURDUE RESEARCH FOUNDATION (US) | 2024-10-03 | — | — | WO | disclosed |
| US-20240208971-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2024-06-27 | — | — | US | disclosed |
| US-11891391-B2 | Inhibitors of kinase networks and uses thereof | PURDUE RESEARCH FOUNDATION (US) | 2024-02-06 | — | — | US | disclosed |
| EP-4233859-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | Purdue Research Foundation (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-4233859-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | Purdue Research Foundation (US) | 2023-08-30 | — | — | EP | disclosed |
| EP-3600287-B1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2023-07-05 | — | — | EP | disclosed |
| EP-3600287-B1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-110662536-B | Kinase network inhibitors and uses thereof | 普渡研究基金会 | 2023-06-23 | — | — | CN | disclosed |
| US-20210371420-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2021-12-02 | — | — | US | disclosed |
| US-20210371420-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2021-12-02 | — | — | US | disclosed |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | PURDUE RESEARCH FOUNDATION | 2021-06-22 | — | — | US | disclosed |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | PURDUE RESEARCH FOUNDATION | 2021-06-22 | — | — | US | disclosed |
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2020-10-01 | — | — | US | disclosed |
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | PURDUE RESEARCH FOUNDATION | 2020-10-01 | — | — | US | disclosed |
| CN-110662536-A | Kinase network inhibitors and uses thereof | 普渡研究基金会 | 2020-01-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308173-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | KDM1B, JMJD6, KDM1A | FLT3 556/4885CDK2 308/4885CCNA1 2225/4885 |
| US-11040973-B2 | Inhibitors of kinase networks and uses thereof | KDM1B, JMJD6, KDM1A | FLT3 556/4885CDK2 308/4885CCNA1 2225/4885 |
| US-12384782-B2 | Inhibitors of kinase networks and uses thereof | KDM1B, JMJD6, KDM1A | FLT3 556/4885CDK2 308/4885CCNA1 2225/4885 |
| US-20210371420-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | KDM1B, JMJD6, KDM1A | FLT3 556/4885CDK2 308/4885CCNA1 2225/4885 |
| US-20240208971-A1 | INHIBITORS OF KINASE NETWORKS AND USES THEREOF | KDM1B, JMJD6, KDM1A | FLT3 556/4885CDK2 308/4885CCNA1 2225/4885 |
| US-11891391-B2 | Inhibitors of kinase networks and uses thereof | KDM1B, JMJD6, KDM1A | FLT3 556/4885CDK2 308/4885CCNA1 2225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.